We have previously reported that FuEP2/Ex2, a soluble decoy receptor for PGE 2 , suppresses tumor growth in an orthotopic xenograft model. To examine whether it has further uses, we examined the effect of FuEP2/Ex2 in an intraperitoneal metastasis model of ovarian cancer cells. We established FuEP2/Ex2-expressing ovarian cancer cells (SKOV/ip-FuEP2/Ex2) and injected them intraperitoneally into female nude mice. Mice injected with SKOV/ip-FuEP2/Ex2 had no ascitic fluid and showed smaller tumor lesions compared to mice injected with vector control cells, with decreased microvessel density and M2 macrophages. To identify molecular targets for combination treatment, we conducted cDNA microarray analysis and found three genes encoding enzyme [matrix metalloproteinase-7 (MMP-7), transmembrane protease serin 4 (TMPRSS4) and cytocrome P450 1B1 (CYP1B1)] to be upregulated in SKOV/ip-FuEP2/Ex2-derived tumors. Administration of TMPRSS4 inhibitor further reduced tumor weight and decreased the number of Ki-67-positive cells in SKOV/ip-FuEP2/Ex2-injected mice. These data indicate a possible EP-targeting strategy using FuEP2/Ex2 in the treatment of ovarian cancer and suggest that dual targeting of EP-mediated signaling and TMPRSS4 may enhance therapeutic value.
Introduction
Of the gynecologic malignancies, ovarian cancer is the leading cause of death, with an overall 5-year survival rate of less than 50%. Worldwide in 2008, approximately 225,500 new cases were diagnosed and there were approximately 140,200 ovarian cancer deaths (1) . The main reason for this is the symptoms, which are subjective and ill-defined, making early diagnosis difficult. Ovarian cancer tends to progress very quickly and metastasize into the peritoneal cavity, features that also contribute to its poor prognosis. Generally, current management of ovarian cancer is cytoreductive surgery followed by chemotherapy with paclitaxel and a platinum analog in combination. Although this management induces a favorable outcome, the long-term survival of ovarian cancer patients remains unsatisfactory (2) and efforts to find a novel, effective treatment strategy are ongoing.
Arachidonic acid-derived biolipids, including prostaglandins, prostacyclins, thromboxanes, and leukotrienes play an important role in regulating various biological processes. They are generated by the cyclooxygenase (COX) or lipoxygenase enzymes. Prostaglandin E 2 (PGE 2 ) is closely associated with cancer cell growth, tumor development and metastasis (3) . Level of PGE 2 and expression of COX are upregulated in animal models and clinical specimens of ovarian cancer (4) (5) (6) . PGE 2 acts by binding to specific cell-surface receptors called E-prostanoid receptors (EPs). There are four subtypes of EP (EP1-EP4), which can be classified into three types based on their signaling features (7) . Consistent with the expression profiles of PGE 2 and COX, increases in EP expression or EP-mediated cellular signaling are observed in ovarian cancer lesions (8) . These reports suggest that PGE 2 -mediated EP signaling is a potential target in the treatment of ovarian cancer.
We reported previously that the soluble fragment of human EP2, which contains second extracellular loops (FuEP2/Ex2), can bind to PGE 2 , inhibits PGE 2 -induced cellular signaling, and suppresses osteolytic prostate tumor growth and endometrial tumor growth (9, 10) . Here, we examine the effect of FuEP2/Ex2 in a peritoneal metastasis model of ovarian cancer to determine which genes exhibit altered expression levels in the tumor lesions. Moreover, the inhibitors and specific siRNA of these genes were used to investigate whether they can act in synergy with FuEP2/ Ex2.
Materials and methods

Cells, animals and in vivo selection.
Human ovarian adenocarcinoma SKOV-3 cells were purchased from European Collection of Cell Cultures (Salisbury, UK). This cell line was maintained in DMEM/F-12 supplemented with 10% FBS, 100 U/ml penicillin G, and 0.1 mg/ml streptomycin sulfate. Five-week-old female nude mice were purchased from Charles River Japan (Yokohama, Japan) and housed under specific pathogen-free conditions. Experimental protocols were carried out according to the Guidelines for the Care and Use of Laboratory Animals of the University of Tokushima School of Medicine and approved by the Animal Care and Use Committee.
To obtain a subclone that prefers to grow intraperitoneally, 2x10 6 SKOV-3 cells were injected into the peritoneal cavity of a female nude mouse. Tumor lesions were separated after 12 weeks and minced with a surgical scalpel. The resulting cell suspension was reseeded and cultured for 1 week. Culture was continued until passage seven. This selected subclone was designed as SKOV/ip.
Stable transfection and expression check.
We used the mammalian expression vector encoding FuEP2/Ex2 cDNA, known as pFUSE-FuEP2/Ex2 (9) . The mock control vector (pFUSE-hFc2, Invivogen, San Diego, CA) or pFUSE-FuEP2/Ex2 (10 µg per 4x10 5 cells) was transfected using a TransFast TM transfection reagent (Promega, Madison, WI) according to the manufacturer's protocol. Transfected cells were treated with 0.5 mg/ml zeocin (Invitrogen, Carlsbad, CA) for 2 weeks, with zeocin exposure repeated every 3 days. After selection, the stable transfectants obtained were maintained in complete culture medium containing 0.2 mg/ml zeocin. These transfectants were designated as SKOV/ip-Fumock and SKOV/ip-FuEP2/Ex2, respectively.
Total RNAs from transfectants were isolated using an RNeasy Mini kit (Qiagen, Valencia, CA). Aliquots of these total RNAs (1 µg/sample) were subjected to RT-PCR under conditions and procedures reported previously (9) . The amplicons were as follows: FuEP2/Ex2-hIgG (covers from 5' end of FuEP2/Ex2 cDNA to 3' end of hIgG Fc sequence in expression vector), IL2ss-hIgG (covers from 5' end of IL2 signal sequence in expression vector to 3' end of hIgG Fc sequence in expression vector), hEP1, hEP2, hEP3, hEP4, hCOX-1, hCOX-2, hmPGES, hcPGES and β-actin. As to the expression of hCOX-1 and hCOX-2 mRNA, quantitative real-time RT-PCR (qRT-PCR) analysis by the ∆∆Ct method was also conducted. The condition and procedure have been described previously (10) . The primer sequences used in this study are listed in Table I and β-actin was amplified as an internal standard. Culture media (CM) from parental SKOV/ip, SKOV/ip-Fumock and SKOV/ip-FuEP2/Ex2 cells were also examined for secreted hIgG Fc-fusion proteins derived from the expression vectors using an hIgG ELISA quantification kit (Bethyl Laboratories, Montgomery, TX).
Proliferation assay. SKOV/ip-Fumock and SKOV/ip-FuEP2/Ex2 cells (5x10 3 cells/well) were plated on 96-well microplates and preincubated overnight at 37˚C. Next, the CM was replaced with 100 µl fresh complete medium; after incubation for 24, 48 and 72 h, the viable cells were counted by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] method.
Peritoneal metastasis model in nude mice. SKOV/ip-Fumock or SKOV/ip-FuEP2/Ex2 cells (2x10 6 cells/mouse) were injected into the peritoneal cavity of nude mice (n=11 in the SKOV/ip-Fumock group and n=10 in the SKOV/ip-FuEP2/Ex2 group) using a 30-gauge syringe. From this time, mice were weighed weekly. After 4 weeks of observation, mice were sacrificed after collecting and measuring the volume of hemorrhagic ascites. All disseminated tumors in the peritoneal cavity were collected, total weight of tumors recorded, then a piece of tumor was selected for biological experiment and fixed in 10% phosphate-buffered formaldehyde for histological analyses. Five tumors in each group were also embedded in Tissue-Tek OCT Compound (Sakura Finetek, Torrance, CA), immediately frozen using liquid nitrogen and stored at -80˚C. This experiment was repeated twice. Histological analyses. The formaldehyde-fixed tissues were embedded in paraffin and sectioned at 4-6 µm. All sections were subjected to H&E staining. Expression of hIgG Fc and Ki-67 were detected by immunohistochemical staining and apoptotic cells were detected by the terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling (TUNEL) assay. The frozen tissues were also sectioned at 4-6 µm. These frozen sections were subjected to immunohistochemical staining for mouse CD31, CD68 and CD163.
To perform quantitative analysis, the number of Ki-67, CD31, CD68 and CD163-positive cells and TUNEL-positive cells per field were counted microscopically. Polyclonal anti-hIgG Fc antibody (Bethyl Laboratories), anti-Ki-67 antibody (Dako, Glostrup, Denmark), monoclonal anti-mouse CD31 (MEC 13.3, BD Pharmingen, San Jose, CA), monoclonal anti-mouse CD68 (FA-11, AbD Serotec, Oxford, UK), and polyclonal anti-mouse CD163 (M-96, Santa Cruz Biotechnology, Santa Cruz, CA) were used as the primary antibodies at dilutions of 1:200, 1:50, 1:50, 1:100 and 1:50, respectively. Before probing with the primary antibodies, sections were blocked with 1% hydrogen peroxide in 50% methanol. The paraffin sections were retrieved by autoclaving in 0.01 M citrate buffer (pH 6.0) for 10 min. Visualization was completed using a ChemMate Envision kit/horseradish peroxidase (for anti-hIgG Fc and anti-Ki-67, Dako), goat anti-rat IgG-HRP (for anti-mouse CD31, Jackson ImmunoResearch Laboratories, West Grove, PA)/3,3'-diaminobenzidine and goat anti-rabbit IgG-HRP (for anti-mouse CD163, Jackson ImmunoResearch Laboratories)/3,3'-diaminobenzidine, respectively. In the TUNEL assay, the DeadEnd Colorimetric TUNEL system (Promega) was employed, following manufacturer's protocol. All sections were counterstained with Mayer's hematoxylin (Muto Pure Chemicals, Tokyo, Japan).
cDNA microarray. Total RNAs from SKOV/ip-Fumock-and SKOV/ip-FuEP2/Ex2-derived tumors were isolated using an RNeasy Mini kit (Qiagen), then used to perform cDNA microarray with GeneChip Human Gene ST Array (Affimetrix, Santa Clara, CA). The detailed procedure has been described previously (11) .
Inhibitor and R NAi studies. SKOV/ip-Fumock and SKOV/ip-FuEP2/Ex2 cells (5x10 3 cells/well) were plated on 96-well microplates and preincubated overnight at 37˚C. The next day, the cells were treated for 24 h with BB-94 (a broad MMP inhibitor whose spectrum includes for MMP-7; Santa Cruz Biotechnology), 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF, a protease inhibitor whose spectrum includes for TMPRSS4; Tokyo Chemical Industry, Tokyo, Japan), and α-naphthoflavone (ANF, an inhibitor of CYP1A and CYP1B; Wako Chemicals, Osaka, Japan) and the number of viable cells determined by the MTT method.
SKOV/ip-Fumock and SKOV/ip-FuEP2/Ex2 cells (1x10 In vivo AEBSF treatment. SKOV/ip-FuEP2/Ex2 cells (2x10 6 cells/mouse) were injected into the peritoneal cavity of nude mice (n=30) using a 30-gauge syringe. Starting the next day, mice were treated daily with intraperitoneal saline (n=10), 5 mg/kg AEBSF (n=10) or 20 mg/kg AEBSF (n=10). Treatment continued for 5 days, followed by a 2-day withdrawal period. Mice were weighed every week. After 4 week of observation, the mice were sacrificed and all disseminated tumors in the peritoneal cavity were collected. Tumor lesions were weighed and fixed in 10% phosphate-buffered formaldehyde for histological analyses.
Statistical analysis. A two-tailed Mann-Whitney U test was employed for comparison of volume of ascites and tumor weights. A two-tailed Student's t-test was employed for comparison of all other data. In all cases, P<0.05 was considered significant.
Results
Characteristics of SKOV/ip-FuEP2/Ex2 cells. RT-PCR
analysis revealed that the SKOV/ip-FuEP2/Ex2 cells expressed FuEP2/Ex2 mRNA. The mobility shift in SKOV/ip-FuEP2/Ex2 at which we amplified IL2ss-hIgG mRNA was due to the inserted FuEP2/Ex2 cDNA sequence (69 bp). ELISA analysis revealed that successful secretion of IgG-fused proteins into CM occurred in both cell lines. The concentrations were calculated to be 61.2±3.3 ng/ml in SKOV/ip-Fumock cells and 77.4±1.2 ng/ml in SKOV/ip-FuEP2/Ex2 cells, respectively (Fig. 1A) . The growth rate under normal conditions was next examined using the MTT method and found to be similar in the two cell types 24, 48 and 72 h after starting the experiment (Fig. 1B) . RT-PCR analysis also revealed similar expression levels of EP1, EP2, EP3, EP4, mPGES and cPGES mRNA in the two cell lines. In contrast, levels of COX-1 and COX-2 mRNA were lower in SKOV/ip-FuEP2/Ex2 cells. The qRT-PCR analysis showed that an 80% decrease in COX-1 mRNA and a 55% decrease in COX-2 mRNA were observed in SKOV/ip-FuEP2/Ex2 cells compared to SKOV/ip-Fumock cells (Fig. 1C) . Macroscopically, no SKOV/ip-FuEP2/Ex2-injected mice were found to bear ascites ( Fig. 2A) . As shown in Fig. 2B , SKOV/ip-Fumock-injected mice had large tumors and hemorrhagic ascites. The tumors in SKOV/ip-FuEP2/Ex2-injected mice were smaller: volume of hemorrhagic ascites and mean tumor weight were significantly lower (Fig. 2B) . Sections from tumor tissue were also subjected to histological analyses. Like typical tumor xenografts, both tumors were undifferentiated with sarcoma-like findings. Immunohistochemical staining for hIgG Fc revealed that both tumors preserved expression of hIgG-derived product (Fig. 2C) . We also quantified Ki-67-labeling indices. The percentage of Ki-67-positive cells did not differ significantly between the two cell lines (Fig. 2C) . We next used ELISA to measure levels of VEGF, IL-6, IL-8 and CXCL1 in CMs and immunohistochemical staining to quantify the number of mCD31 (as index for microvessel density)-, mCD68 (for total macrophage)-and mCD163 (for M2 macrophage)-positive cells in tumor lesions. ELISA analyses revealed to be significantly lower levels of VEGF, IL-6, IL-8 and CXCL1 in SKOV/ip-FuEP2/Ex2 CM than in SKOV/ip-Fumock CM (Fig. 3A) . As shown in Fig. 3B , the numbers of CD31-and CD163-positive cells were significantly lower in SKOV/ip-FuEP2/ Ex2-derived tumors than in SKOV/ip-Fumock-derived tumors, whereas the number of CD68-positive cells did not differ significantly between the two cell lines.
Effect of secreted
Determination of combinatorial target with FuEP2/Ex2. By using cDNA microarray analysis, we examined differential gene expression between SKOV/ip-Fumock-derived and SKOV/ip-FuEP2/Ex2-derived tumors. Setting the cut-off value of fold change as >4.0 and <0.25, respectively, revealed 6 upregulated genes and 8 downregulated genes in the SKOV/ ip-FuEP2/Ex2-derived tumor (Table II) . Three upregulated genes encoded enzymes, namely MMP-7 (4.471-fold), TMPRSS4 (4.348-fold) and CYP1B1 (4.000-fold), each of which has previously been shown to be overexpressed in several types of cancer (12) (13) (14) (15) (16) . To validate the result of cDNA microarray, MMP-7, TMPRSS4 and CYP1B1 mRNA from tumor tissue was detected by RT-PCR. All mRNA levels in SKOV/ip-FuEP2/Ex2-derived tumors appeared to be upregulated compared with those in SKOV/ip-Fumock-derived tumors (Fig. 4) .
Effect of inhibition and knockdown of MMP-7, TMPRSS4 and CYP1B1 on growth of ovarian cancer cells.
To examine whether MMP-7, TMPRSS4 or CYP1B1 provides a possible target in combination with EP-mediated signaling inhibition, we tested the effects of inhibition and knockdown to their molecules in SKOV/ip-Fumock and SKOV/ip-FuEP2/Ex2 cells. First, BB-94 (inhibitor for MMP-7), AEBSF (for TMPRSS4) and ANF (for CYP1B1) were used to conduct a toxicity assay. BB-94 treatment did not affect cell viability of SKOV/ip-Fumock cells at any dose level; in SKOV/ip-FuEP2/Ex2 cells, significant reduction of cell viability was found in the highest dose group only (Fig. 5A) . Comparing SKOV/ip-Fumock and SKOV/ip-FuEP2/Ex2 cells (Fig. 5A) . At the highest dose, cell viability was also significant lower in SKOV/ip-FuEP2/Ex2 than in SKOV/ip-Fumock cells. Treatment with ANF did not affect viability of SKOV/ip-Fumock cells at any dose (Fig. 5A ) and significant reduction of SKOV/ip-FuEP2/Ex2 cell viability was found in only the highest dose group (Fig. 5A ). As observed with AEBSF treatment, viability of SKOV/ip-FuEP2/Ex2 cells was also significant lower than SKOV/ip-Fumock cells at the highest dose.
Next, we conducted a knockdown assay using specific siRNA for MMP-7, TMPRSS4 and CYP1B1. RT-PCR analysis revealed that all kinds of siRNA worked effectively and specifically in both SKOV/ip-Fumock and SKOV/ip-FuEP2/Ex2 cells (Fig. 5B ). Using these knocked down cells, we assessed growth activity by the trypan blue-exclusion method. As shown in Fig. 5B , there were significantly fewer SKOV/ip-FuEP2/Ex2 cells than SKOV/ip-Fumock cells following treatment with TMPRSS4 siRNA.
Effect of AEBSF treatment in a SKOV/ip-FuEP2/Ex2
-based peritoneal metastasis model. Based on our in vitro results, inhibition of TMPRSS4 is a likely candidate to provide synergistic suppression of cancer cell growth in vivo under depletion of EP-mediated signaling. To test this proposal, we intraperitoneally injected SKOV/ip-FuEP2/Ex2 cells and administered saline or AEBSF (5 or 20 mg/kg) to the nude mice. At experiment end-point, average body weight in the 20 mg/kg AEBSF-treated group was slightly lower than in the other two groups, but the difference was not significant (21.2±1.06 g saline, 21.0±0.87 g 5 mg/kg AEBSF, 20.2±1.61 g 20 mg/kg AEBSF, respectively; data not shown). Tumor weight decreased dose-dependently with AEBSF (Fig. 6A) . Using paraffin-embedded sections of tumor lesion, Ki-67-labeling indices were quantified and TUNEL-positive apoptotic cells were counted. The percentage of Ki-67-positive cells was significantly lower in AEBSFtreated groups than the saline-treated group, while the numbers of TUNEL-positive cells did not differ significantly (Fig. 6B) . Total RNAs from tumor tissue were isolated using an RNeasy Mini kit and then aliquots of these total RNAs (1 µg/sample) were subjected to RT-PCR. The amplicons were hMMP-7, hTMPRSS4, hCYP1B1 and β-actin. The primer sequences are listed in Table I and β-actin was amplified as an internal standard. 
Discussion
Cellular signaling via the PGE 2 -EP receptor is involved in the growth, progression and metastasis of ovarian cancer as well as many other cancer types (8, 17, 18) . Indeed, a strategy that blocks production of PGE 2 or EP receptor-mediated signaling showed a reduction in cancer cell growth in vitro and in vivo (19) (20) (21) . Heterozygous deletion of the COX-2 gene also reduced growth of ovarian cancer (22) . These reports suggest that cellular signaling via the PGE 2 -EP receptor can be a target for therapy of ovarian cancer and its metastasis. Therefore, we established FuEP2/Ex2-expressing ovarian cancer cells and attempted to evaluate the suppressive effect of FuEP2/Ex2, which functions as a decoy receptor to PGE 2 , on tumor growth in a peritoneal metastasis model.
The FuEP2/Ex2-expressing cells, SKOV/ip-FuEP2/Ex2, grew at a similar rate to vector-control cells. Surveying the expression status of EP receptors and enzymes involved in producing PGE 2 revealed that COX-1 and COX-2 mRNA were downregulated in SKOV/ip-FuEP2/Ex2 cells. Exogenous PGE 2 stimulates expression of COX-1 and COX-2 mRNA (23, 24) , so this result indicates that FuEP2/Ex2 cuts off the positive feedback loop of the PGE 2 -COXs axis. Similar growth rate may be due to compensation by other factors under culture conditions. An in vivo experiment revealed that FuEP2/Ex2 inhibits ovarian tumor growth with complete disappearance of ascetic fluid and decreased tumor weight. In SKOV/ip-FuEP2/Ex2 cells, production of VEGF, CXCL1, IL-6 and IL-8, which contributes to the generation of ascitic fluid and enhancement of tumor growth in ovarian cancer (25) (26) (27) (28) , is suppressed under in vitro conditions. These factors can also be regulated by PGE 2 (29) (30) (31) (32) . Our data suggest that blockade of EP receptor-mediated cell signaling by FuEP2/Ex2 also influences the production of these factors and that these reductions may cause the disappearance of ascetic fluid and the decreased tumor weight. Immunohistochemical staining showed decreased microvessel density and M2 macrophages in SKOV/ip-FuEP2/Ex2-derived tumors. M2 macrophage is an activator of tumor growth and a suppressor of tumor immunity, and PGE 2 , VEGF and IL-6 are known to be an inducer of differentiation into M2 macrophages (33) . These results further strengthen the suggestion that FuEP2/Ex2 can suppress angiogenesis, which is one of the most important events in intraperitoneal metastasis of ovarian cancer and that its growth suppression is also associated with blocking of differentiation into M2 macrophages by secreted FuEP2/Ex2. cDNA microarray analysis revealed that several genes are up-or downregulated in the SKOV/ip-FuEP2/Ex2-derived tumor lesion. We focused on upregulated genes because of their possible role in cell survival under depletion of EP receptormediated cell signaling. Of the upregulated genes, we chose MMP-7, TMPRSS4 and CYP1B1, and analyzed whether interference to these genes synergistically affects neutralization of EP receptor-mediated cell signaling by FuEP2/Ex2. The reason why we chose these three genes is that they have enzymatic function, allowing use of their inhibitors for further analysis. Toxicity assays using their inhibitors showed the TMPRSS4 inhibitor AEBSF to have toxic effect on both SKOV/ip-Fumock and SKOV/ip-FuEP2/Ex2 cells. At the highest dose, its toxicity was greater towards SKOV/ip-FuEP2/Ex2 than SKOV/ ip-Fumock cells. Both the MMP-7 inhibitor BB-94 and the CYP1B1 inhibitor ANF had weaker effects than AEBSF in both cell lines. Experiments using siRNA showed that the number of SKOV/ip-FuEP2/Ex2 cells was lower than SKOV/ip-Fumock cells when treated with TMPRSS4 siRNA. These results suggest that TMPRSS4 inhibition has the potential to enhance the effect of FuEP2/Ex2. However, we were concerned that the toxic and suppressive effects of targeting TMPRSS4 are not so obvious in vitro. Therefore, we checked the expression status of this gene by performing another cDNA microarray analysis under in vitro conditions. This attempt revealed that the degree of upregulation in SKOV/ip-FuEP2/Ex2 was apparently decreased (1.34-fold; data not shown). This indicates that upregulation of these genes is due to interactions with cells from the host rather than FuEP2/Ex2 itself. Therefore, we continued to analyze the effect of AEBSF in our SKOV/ip-FuEP2/Ex2-based peritoneal metastasis model.
Treatment of AEBSF further suppressed tumor growth in the SKOV/ip-FuEP2/Ex2-based peritoneal metastasis model. This suppression was dose-dependent without toxicity. Immunohistochemical analyses revealed that this suppression is associated with proliferative status of cancer cells rather than apoptotic induction, unlike the difference between SKOV/ip-Fumock and SKOV/ip-FuEP2/Ex2 cells. In contrast, single administration of AEBSF did not affect cancer cell growth and ascites formation (data not shown). These results may suggest that AEBSF could have an effect in the presence of FuEP2/Ex2. We also tested the effect of single or combination treatment of AEBSF and meloxicam, a selective COX-2 inhibitor; however, no suppressive effects on cancer cell growth and ascites formation were observed (data not shown). This indicates that some prostanoids derived from COXs suppress ovarian tumor growth and that specific inhibition of EP receptor-mediated cell signaling is a valid therapeutic strategy for peritoneal metastasis of ovarian cancer. TMPRSS4 promotes tumor growth, invasion, metastasis, and epithelialmesenchymal transition (15, 34) . Considering the function of TMPRSS4 in cancer cells, our data showing inhibition of cancer cell growth in SKOV/ip-FuEP2/Ex2-based peritoneal metastasis model are reasonable, and the ineffectiveness of AEBSF alone or in combination with meloxicam may be a result of the expression level of TMPRSS4 being insufficient to suppress cancer cell growth.
Our above results strongly suggest potential targets for treatment of ovarian cancer metastasis that is positive for EP (especially EP2 and EP4) and TMPRSS4. At present, there have been few reported clinical studies using EP antagonists (35, 36) and no specific inhibitor for TMPRSS4 has yet been developed. If a potent, specific, and safe way to attack these targets is exploited, it may provide a promising therapeutic strategy for the repression of ovarian cancer metastasis by combining existing agents for ovarian cancer therapy.
